Insights
Recon takes an analytical look behind select developments in healthcare
Keep up with Recon Strategy Insights
Get an email each time we publish a new article
Search
- By Lilian Zhang, Jason Brauner, and Marc Herant
In our previous analyses (2023[1] and 2024[2]), we tracked two oncology development cohorts using a Kaplan–Meier framework to visualize how quickly programs reach a terminal outcome—either an FDA appr…
- By Chisom Chukwu
About the author: Chisom is currently a high school senior attending Boston Latin School. She spent the summer of 2025 with Recon Strategy as a paid intern assigned a project to research the effect of…
- By Marc Herant
Exercise with cancer: it’s about more than fitness
Retrospective observational studies very frequently highlight the correlation of various lifestyle characteristics with outcomes, but most of the tim…
- By Jacob Wiesenthal and Tory Wolff
A new AJMC study from consulting firm Recon Strategy is the first to show how advanced primary care techniques, previously proven in older Medicare populations, could also deliver substantial savings …
- By Jacob Wiesenthal and Tory Wolff
- By Martha Deja and Sarah Dolman
Download a PDF of this paper here. A comprehensive slide-deck (including a breakdown by therapeutic area) and a complete list of assets deals are also available; click [datapack] to access.
Ear…
- By Maggie Pickard, Allison Cremer, and Jason Brauner
We explore four hypothesized value drivers of platform-based companies and evaluate the actual value achieved 10-15 years out from initial capital raise. We found that discovery platforms showed the highest lead asset success rates, significantly more out-licensing activity than non-platforms, and accounted for nearly all multi-asset approvals within our cohort. All platform types showed increased survivability and more licensing opportunities.